CN119053618A - 嵌合ilt受体组合物和方法 - Google Patents

嵌合ilt受体组合物和方法 Download PDF

Info

Publication number
CN119053618A
CN119053618A CN202380026753.7A CN202380026753A CN119053618A CN 119053618 A CN119053618 A CN 119053618A CN 202380026753 A CN202380026753 A CN 202380026753A CN 119053618 A CN119053618 A CN 119053618A
Authority
CN
China
Prior art keywords
cells
domain
cell
receptor protein
chimeric receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380026753.7A
Other languages
English (en)
Chinese (zh)
Inventor
J·H·贝利
M·T·唐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enkirt Medical Co ltd
Original Assignee
Enkirt Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enkirt Medical Co ltd filed Critical Enkirt Medical Co ltd
Publication of CN119053618A publication Critical patent/CN119053618A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202380026753.7A 2022-02-04 2023-02-03 嵌合ilt受体组合物和方法 Pending CN119053618A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306514P 2022-02-04 2022-02-04
US63/306,514 2022-02-04
PCT/US2023/061966 WO2023150698A2 (en) 2022-02-04 2023-02-03 Chimeric ilt receptor compositions and methods

Publications (1)

Publication Number Publication Date
CN119053618A true CN119053618A (zh) 2024-11-29

Family

ID=87553009

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380026753.7A Pending CN119053618A (zh) 2022-02-04 2023-02-03 嵌合ilt受体组合物和方法

Country Status (8)

Country Link
US (2) US12269861B2 (https=)
EP (1) EP4473006A4 (https=)
JP (1) JP2025505546A (https=)
KR (1) KR20240156654A (https=)
CN (1) CN119053618A (https=)
AU (1) AU2023216270A1 (https=)
CA (1) CA3248806A1 (https=)
WO (1) WO2023150698A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119569893B (zh) * 2023-09-06 2025-10-31 上海恩凯细胞技术有限公司 特异性靶向肿瘤的嵌合抗原受体细胞及其制备方法和应用
CN119569892A (zh) * 2023-09-06 2025-03-07 上海恩凯细胞技术有限公司 特异性靶向肿瘤非经典hla分子的嵌合抗原受体的应用
CN119569891B (zh) * 2023-09-06 2025-09-05 上海恩凯细胞技术有限公司 用于癌症治疗的靶向非经典hla分子的嵌合抗原受体的应用
CN120248130A (zh) * 2023-12-28 2025-07-04 上海恩凯细胞技术有限公司 特异性靶向肿瘤的转基因重组免疫细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201206559D0 (en) * 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
EP3209769B1 (en) * 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
NZ748929A (en) 2016-06-03 2025-11-28 Invectys Anti hla-g specific antibodies
KR20180064612A (ko) * 2016-12-05 2018-06-15 삼성디스플레이 주식회사 표시 장치
AU2019328677A1 (en) 2018-08-31 2021-04-01 Invectys SA Chimeric antigen receptors against multiple HLA-G isoforms
US20200190163A1 (en) * 2018-10-26 2020-06-18 Lijun Wu Humanized bcma-car-t cells
IL285909B2 (en) * 2019-03-15 2023-04-01 Cartesian Therapeutics Inc Single-stranded variable segments directed against bcma
JP7739261B2 (ja) 2019-08-09 2025-09-16 エイ２・バイオセラピューティクス・インコーポレイテッド ヘテロ接合性の喪失に応答する細胞表面受容体

Also Published As

Publication number Publication date
JP2025505546A (ja) 2025-02-28
WO2023150698A2 (en) 2023-08-10
KR20240156654A (ko) 2024-10-30
EP4473006A2 (en) 2024-12-11
US20230348560A1 (en) 2023-11-02
AU2023216270A1 (en) 2024-08-15
CA3248806A1 (en) 2023-08-10
WO2023150698A3 (en) 2023-10-05
EP4473006A4 (en) 2026-02-25
US20250257114A1 (en) 2025-08-14
US12269861B2 (en) 2025-04-08

Similar Documents

Publication Publication Date Title
US12103957B2 (en) Nyeso tcr
EP3946621B1 (en) Mage a4 t cell receptors
CN107922489B (zh) κ骨髓瘤抗原嵌合性抗原受体和其用途
CN108026151B (zh) Pd-1-cd28融合蛋白及其在医学中的用途
US12269861B2 (en) Chimeric ILT receptor compositions and methods
EP3833682B1 (en) Suicide module compositions and methods
WO2021030153A2 (en) Engineered t cell receptors and uses thereof
WO2022098750A1 (en) Hla class ii-restricted tcrs against the kras g12>v activating mutation
WO2019182996A1 (en) Antibody-interferon fusion proteins for enhancing adoptive t cell therapies for the treatment of cancer
CA3084190A1 (en) Methods for enhancing and maintaining car-t cell efficacy
JP2021532814A (ja) Ｈａ−１特異的ｔ細胞受容体およびその使用
WO2022049217A1 (en) System for inducible expression of an adapter in immune cells
CN121941503A (zh) 嵌合ilt受体组合物和方法
KR102957751B1 (ko) Mage a4 t 세포 수용체
AU2024316791A1 (en) Chimeric ilt receptor compositions and methods
HK40050291A (en) Suicide module compositions and methods
HK40050291B (en) Suicide module compositions and methods
EA041624B1 (ru) Prame-специфический t-клеточный рецептор и варианты его применения
HK1229842A1 (en) Novel synthetic biology-based adcc technology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination